Happy Authors

Recently Published Articles
  • 2020, April

    case report

    Pseudo Metabolic Acidosis in the Setting of Hypertriglyceridemia: A Case ReportOpen Access

    PDF213.87 KB 213.87 KB
    Full-Text (HTML)
    Abstract [+]

    Low serum bicarbonate, with or without an elevated anion gap, can indicate metabolic acidosis. High anion gap metabolic acidosis is due to the unmeasured anions. Hypertriglyceridemia can also be associated with spuriously low serum bicarbonate levels due to lab interference. We present a 44-year-old woman who presented with anion gap metabolic acidosis in the presence of severe hypertriglyceridemia.


    Hypertriglyceridemia; Acid-base disorders; Low serum bicarbonate; Metabolic acidosis.

  • 2019, September

    retrospective study

    Morbidity and Mortality Associated with Development of Hypogammaglobulinemia after RituximabOpen Access

    PDF394.56 KB 394.56 KB
    Full-Text (HTML)
    Abstract [+]


    Low-levels of gamma globulin are associated with a risk of infection, and complications of hypogammaglobulinemia are often observed in hematologic malignancies. In chronic lymphocytic leukemia (CLL), IgG≤600 mg/dL is reportedly associated with higher risks of infection. The objective was to determine the risks of hypogammaglobulinemia and infection in malignant lymphomas for which rituximab that targets B-cells is used.


    A retrospective analysis of data from medical records of patients with malignant lymphomas treated with rituximab-containing therapy at our hospital between April 2014 and March 2016 was performed to assess the risks of infections through an evaluation of IgG levels and hospitalizations for and deaths due to infections in patients hospitalized with infections during this period.


    From April 2014 to March 2016, 128 patients with malignant lymphomas received rituximab-containing therapy at our hospital, and 94 (61%) of these patients had IgG levels measured. These 94 patients were included in the analysis. The histological types were as follows: 30 had follicular lymphoma (FL), 17 had indolent non-Hodgkin’s lymphoma (iNHL), 42 had diffuse large B-cell lymphoma (DLBCL), and 5 had mantle cell lymphoma (MCL). The mean minimum immunoglobulin G (IgG) level in patients hospitalized for infection was 546 mg/dL and was 628 mg/dL in those not hospitalized (p=0.6). Although a significant difference was not observed, IgG levels tended to be low in hospitalized patients with infection. In addition, there were 4 patients with mean IgG levels that were 600 mg/dL or less in the 6-months immediately prior to hospitalization. Among these 2 died of infection.


    Low-levels of gamma globulin are associated with a risk of mortality due to infections in malignant lymphomas.


    Hypogammaglobulinemia; Malignant lymphoma; Rituximab.


    CLL: Chronic lymphocytic leukemia; FL: Follicular lymphoma; iNHL: Indolent non-Hodgkin’s lymphoma; DLBCL: Diffuse large B-cell lymphoma; MCL: Mantle cell lymphoma; FN: Febrile neutropenia.

  • 2019, August

    original research

    Efficacy and Safety of Clarithromycin, Lenalidomide and Dexamethasone (Bird) Therapy for Japanese Patients with Relapsed or Refractory Multiple MyelomaOpen Access

    PDF415.88 KB 415.88 KB
    Full-Text (HTML)
    Abstract [+]


    It is difficult for the elderly, those with complications, and those who live in remote areas to visit the hospital, and as a result, there are limits on the drugs they are able to use. It is therefore effective to prescribe such patients oral medications that have few adverse effects and in regimens that require few hospital visits. Clarithromycin can induce cell death by autophagy and it has a direct antitumor effect. There have been reports of the outcomes of Lenalidomide and Dexamethasone therapy with Clarithromycin which is administered orally and is safe on multiple myeloma. However, in Japan, there have been few studies. Here, we report on Clarithromycin, Lenalidomide and Dexamethasone therapy in our hospital.


    We analyzed 7 patients with relapsed refractory or refractory multiple myeloma who were treated at this hospital between January 2012 and December 2014. The Clarithromycin, Lenalidomide and Dexamethasone therapy were administered in a 28-day cycle as follows: Clarithromycin 400 mg/day for 28-days, Lenalidomide 15 mg/day for 21-days, and Dexamethasone was administered in a dose of 20 mg once per week. The response criteria used were standard International Myeloma Working Group (IMWG) Uniform Response Criteria. and adverse events were graded according to the national cancer institute-common terminology criteria for adverse events (NCI-CTCAE) Ver. 4. Statistical analysis was performed using Easy R (EZR).


    The response to Clarithromycin, Lenalidomide and Dexamethasone therapy were selective catalytic reduction (sCR) in 2 patients, CR in 1 patient, per rectum (PR) in 3 patients, and standard deviation (SD) in 1 patient. Response rates of PR or better were observed in 86% of the patients. Duration of response was median 316-days (range, 160-522-days). Median oculus sinister (OS) period was 1,907 days. Median OS following discontinuation of the study was 1,385 days. Hematological adverse events were G1-2 anemia in 3 patients and G3-4 anemia in 1 patient. G1-2 thrombocytopenia was observed in 1 patient and G3-4 thrombocytopenia was observed in 1 patient. Leukopenia of G1-2 was observed in 6 patients but G3 was not observed. Non-hematological adverse events were G1-2 liver disorder in 6 patients, G1-2 skin rash in 3 patients, and G1-2 constipation in 2 patients. G4 adverse events were fainting and duodenal ulcer in 1 patient each.


    Clarithromycin, Lenalidomide and Dexamethasone can be safely and effectively administered in the relapsed refractory multiple myeloma


    Multiple myeloma; Bird; Clarithromycin, lethal dose (Ld).

  • 2019, July

    case report

    Early Onset, But Late Diagnosis of a Rare DiseaseOpen Access

    PDF313.08 KB 313.08 KB
    Full-Text (HTML)
    Abstract [+]

    One of the most common sphingolipidosis, Gaucher disease (GD) remains rare till date. A case report of a 56-year-old patient diagnosed with GD is presented herein. Her sister was known to have Gaucher disease. Her personal medical record consisted of splenectomy, anemia, recurrent infections, and bone lesions at a young age. Taking into consideration her personal and familial history, the clinical and paraclinical examinations, she was diagnosed with Gaucher disease which was confirmed with enzyme and gene testing. Upon introduction of specific enzyme replacement treatment for Gaucher patients,much evidence demonstrated the substantial improvement of hematological and visceral parameters. However, it has been observed that the bone tissue does not respond equally to the treatment.
    Learning Points
    • The physician should always investigate the splenomegaly of unknown etiology before deciding to do a splenectomy
    • Bone lesions in Gaucher disease are sometimes irreversible, hence the importance of early diagnosis of this rare disease
    Gaucher disease; Bone lesion; Splenomeagly.
    GD: Gaucher disease; Hb: Hemoglobin; MRI: Magnetic resonance imaging; ERT: Enzyme replacement therapy.

About the Journal

Internal Medicine – Open Journal (IMOJ) is an online open access journal that serves as a one-stop reference for Internal Medicine or General Medicine.

Internal Medicine is a branch of medicine that deals with prevention, diagnosis, and treatment of adult diseases.

Openventio aims to act as a complete reference point for all Internal Medicine professionals and students across the world.

Aims and Scope

Internal Medicine – Open Journal is dedicated for promoting patient care, research, education in primary care, general medicine, and hospital medicine.

IMOJ covers a wide array of subjects as given below

  • Immunization
  • Obesity and weight management
  • Vascular biology
  • Internal medicine
  • Menopause
  • Cardiovascular disease
  • Stem cell research
  • Translational medicine

Openventio wants to encourage participation of ever growing medical community to ensure data gets recorded and passed on to new practitioners in the field of medicine.

Submissions for this Journal are accepted from all practitioners and students of Internal medicine, from experts in the field to novices who are just starting to learn and understand Internal medicine.

The contributors of IMOJ includes doctors, nurses, research assistants, local community practitioners, manufacturers and students of various universities and general communities from different parts of the world.

The journal welcomes all types of articles such as original research, review, case-report, mini-review, editorial, short-communication, book review, opinion, commentary, letter to the editor, conference proceedings, technical report, errata, illustrations, etc. This journal accepts all type of manuscripts providing knowledge on various aspects of internal medicine.

We are open to receive comments or any corrections from any potential scientists to improve the quality of our Journal. Any comments /feedback from any potential scientists to improve the journal quality would be appreciated.